Ownership and insider activity for NuCana plc (NCNA): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
NuCana plc is a clinical-stage biopharmaceutical firm dedicated to pioneering advanced therapies for oncology. Its innovative product pipeline is underpinned by a proprietary ProTide technology platform.
Price
| Price | $1.30 |
| Market Cap | $8M |
| Exchange | NASDAQ |
| Country | GB |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $20.0M | $86.7M | $77.0M | $52.0M | $87.4M | $60.3M | $41.9M | $17.2M | $6.7M | $24.3M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | $2.6M | $4.8M | $4.8M | $9.1M | $10.6M | $8.2M | $7.0M | $5.8M | $4.6M | $1.9M |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $25.8M | $94.0M | $83.6M | $65.2M | $101.8M | $71.6M | $54.9M | $25.0M | $12.3M | $26.9M |
| Property, Plant & Equipment | $18000 | $358000 | $427000 | $1.1M | $1.2M | $851000 | $866000 | $521000 | $197000 | $658000 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | $1.4M | $1.9M | $3.1M | $4.0M | $4.8M | $2.4M | $2.4M | $2.1M | $2.2M | $2.2M |
| Total Assets | $27.2M | $96.4M | $87.2M | $70.3M | $107.8M | $77.5M | $58.3M | $27.8M | $14.8M | $29.8M |
| Accounts Payable | $728000 | $1.1M | $2.5M | $2.4M | $2.3M | $1.8M | $4.8M | $3.4M | $2.7M | $522000 |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $2.0M | $2.9M | $5.6M | $6.2M | $8.1M | $11.7M | $19.3M | $12.7M | $8.7M | $4.8M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $2.0M | $2.9M | $5.6M | $6.7M | $8.6M | $11.9M | $19.8M | $12.9M | $8.8M | $5.5M |
| Retained Earnings | -$22.3M | -$45.2M | -$58.8M | -$80.1M | -$110.6M | -$149.7M | -$180.6M | -$207.7M | -$224.3M | -$252.3M |
| Total Equity | $25.2M | $93.4M | $81.6M | $63.5M | $99.2M | $65.5M | $38.5M | $14.9M | $6.0M | $24.3M |
| Total Debt | 0 | 0 | 0 | $806000 | $645000 | $371000 | $639000 | $396000 | $190000 | $676000 |
| Net Debt | -$20.0M | -$86.7M | -$77.0M | -$51.2M | -$86.7M | -$59.9M | -$41.3M | -$16.8M | -$6.6M | -$23.6M |
| Working Capital | $23.8M | $91.1M | $78.0M | $59.0M | $93.7M | $59.9M | $35.6M | $12.3M | $3.6M | $22.1M |
Financial Health
| Debt / Equity | 0.03 |
| Current Ratio | 5.60 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -12.10 |
Profitability
| Return on Equity | -120.66% |
| Return on Invested Capital | -77.17% |
| Return on Assets | -98.39% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: CASI · CLGN · CLSD · ENLV · GDTC · LSTA · MTVA
Explore sector: Healthcare · Biotechnology
More sections of NCNA: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks